

August 5, 2026

BSE Limited

The Listing Department
Phiroze Jeejeebhoy Towers
25th Floor, Dalal Street
Fort, Mumbai 400 001
Maharashtra, India

BSE Scrip Code: 544309

National Stock Exchange of India Limited

The Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051
Maharashtra, India

NSE Symbol: IKS

Dear Sir/Ma'am,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith investor presentation on the financial results of the Company for the quarter ended June 30, 2026.

The said presentation is also being uploaded on the website of the Company at the <https://ikshealth.com/investor-relations/>

Request you to take it on record and disseminate the same on your website.

Thanking you.

Yours sincerely,

For Inventurus Knowledge Solutions Limited

Sameer Chavan

Company Secretary and Compliance Officer

Membership No. F7211

Encl: As above


IKS Health

Q1 FY 27 Investor Presentation


Disclaimer

This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company's current visibility on market movements, client discussions, and related factors. Inventurus Knowledge Solutions Limited does not assume an obligation to update or revise any forward-looking statements.

IKS Health – a comprehensive healthcare enablement platform empowering provider organizations



IKS Health: 5 strategic pillars of execution



Awards and Recognition



US Patent US 12,619,923 B2 for Engagement Learning Engine

AI-driven "Awareness-Ability-Willingness" (AAW) behavioral modeling powers IKS Health's patient access solutions including MyCareHub which enhance patient engagement and optimize patient scheduling.



2026 Dallas-Fort Worth Titan 100

Titan CEO – Sachin K. Gupta, Founder & Global CEO



Best CFO & Finance Strategy Excellence Awards 2026

1. Excellence in Investor Relations (Organisational category)
2. Best CFO in Healthcare – Nithya Balasubramanian, Whole-time Director & Group CFO (Individual category)

Awards and Recognition



FE HR Awards 2026
Excellence in Onboarding & Role Enablement




American Medical Group Association (AMGA)
Distinguished Corporate Partner Award 2026




Axia Women's Health
IKS Health partnership for medical coding delivered \$12 Million in annual cash impact with 96%+ coding accuracy and 37% lower coding related denials

IKS Health enables care transformation *across the patient journey*




Q1 – Strong growth while delivering *continuous margin expansion*



Q1 FY 27: Growing *faster than market* with *strong margins*

Revenue
INR Mn




Q1 FY26 Q4 FY26 Q1 FY27

↑ 20.7% YoY

↑ 4.2% QoQ

EBITDA
INR Mn




Q1 FY26 Q4 FY26 Q1 FY27

↑ 24.0% YoY (even higher if not for one-time acquisition costs)

↓ 1.8% QoQ (due to one-time acquisition costs and reduction in currency gains)

PAT
INR Mn




Q1 FY26 Q4 FY26 Q1 FY27

↑ 27.8% YoY

↓ 5.9% QoQ

Adjusted PAT*
INR Mn



Q1 FY26 Q4 FY26 Q1 FY27


↑ 28.0% YoY

↓ 5.1% QoQ


*Adjusted PAT is adjusted for amortization of intangible assets recognised on acquisition which is a non-cash expense.

Q1 FY 27 – Continued strong *cash generation* supporting growth aspirations

OCF & FCF INR Mn



Net Debt INR Mn




Key deal wins



**Premier
California
Health System**

Strategic partnership with premier integrated health system in California for a comprehensive clinical data migration for an acquired hospital, seamlessly unifying legacy records into their enterprise EHR. Establishes a framework that positions IKS as a preferred partner for additional facility migrations across the growing group footprint.



**National
Musculoskeletal
Leader**

Reuniting with one of the leaders in musculoskeletal space. The collaboration focuses on modernizing end-to-end RCM functions. By optimizing back-office functions, the clinical provider can better focus on delivering highly customized, life-enhancing physical interventions to patients nationwide.



ADVOCATEHEALTH

One of country's top health systems Advocate Health, an existing client, is significantly expanding its partnership across RCM including coding in volume and value efforts across its entire network in the acute and ambulatory space.




StrideCare

Existing customer StrideCare is a large Texas multi-specialty physician group that acquired a vein, vascular, and podiatry specialty group and extended RCM services, indicating organic growth and practice expansion.


Q1 FY 27 – Improving EPS and maintaining high ROE

EPS ₹



EPS is calculated as profit for the period divided by weighted average number of equity shares as defined in IND AS 33.

ROE %*



Return on Equity is calculated as profit for the period divided by average equity balance during the period.

*ROE declined due to increased equity base from revaluation of Abridge, alongside lower earnings from reduced currency gains and one-time acquisition costs.

Financials – Summary INR millions

Particulars	INR Mn				
	Q1 FY 27	Q1 FY 26	YoY%	Q4 FY 26	QoQ%
Revenue USD mn	97	87	12.0%	95	2.5%
Revenue	8,936	7,401	20.7%	8,577	4.2%
Forex Gain/ (Loss)	12	12	3.2%	352	-96.6%
Employee benefit expense excluding ESOP	4,332	3,871	11.9%	4,011	8.0%
Other Expenses*	1,449	1,075	34.8%	1,743	-16.9%
EBITDA excluding ESOP	3,167	2,467	28.4%	3,175	-0.2%
EBITDA excluding ESOP %	35.4%	33.3%	2.1%	37.0%	-1.6%
ESOP Cost	218	89	145.4%	173	26.2%
EBITDA	2,949	2,378	24.0%	3,002	-1.8%
EBITDA %	33.0%	32.1%	0.9%	35.0%	-2.0%
Finance cost	101	181	-44.1%	127	-20.2%
Depreciation and amortisation	343	279	22.9%	341	0.7%
Interest income	57	31	85.3%	49	17.2%
Profit before exceptional items and tax	2,563	1,949	31.5%	2,584	-0.8%
Profit before exceptional items and tax %	28.7%	26.3%	2.3%	30.1%	-1.4%
Tax expense	572	433	32.0%	470	21.7%
Profit for the period before Share of Associates	1,990	1,515	31.4%	2,114	-5.8%
Profit for the period before Share of Associates %	22.3%	20.5%	1.8%	24.6%	-2.4%
Share of Profit/(Loss) from Associates (net of tax)	(53)		0.0%	(54)	-1.9%
Profit for the period	1,937	1,515	27.8%	2,060	-5.9%
Profit for the period %	21.7%	20.5%	1.2%	24.0%	-2.3%
Amortisation of Intangible assets	216	167	29.2%	210	2.8%
Adjusted Profit for the period	2,153	1,682	28.0%	2,269	-5.1%
Adjusted Profit for the period %	24.1%	22.7%	1.4%	26.5%	-2.4%

*Includes acquisition expenses incurred in current quarter and last quarter

Other KPI Metrics

Particulars	Q1 FY 27	Q1 FY 26	Q4 FY 26
Annualised Adjusted EBITDA per employee in INR mn	0.99	0.81	0.98
Revenue from Top 10 customers INR mn	4,808	3,213	4,525
Contribution from Top 10 customers	53.8%	43.4%	52.8%
Revenue from Top 5 customers INR mn	3,759	2,349	3,564
Contribution from Top 5 customers	42.1%	31.7%	41.5%
Ageing of Top 10 clients (number of years)	5.76	5.54	5.42
Ageing of Top 5 clients (number of years)	7.41	5.52	5.56
FCF Yield (%)	89.9%	84.5%	62.1%


A decade of *consistent profitable growth*

INR Mn


Revenue PAT

28.7%
Revenue CAGR

46.4%
PAT CAGR



Medium-Term Financial Outlook



Strategic Outlook: Sustained EBITDA expansion without significant dilution of Equity.

Thank You